NASDAQ · Medical - Devices
BVS (BVS) Stock
$13.12
-0.68%
NASDAQ: BVS
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Bioventus (BVS) Stock Looks Overvalued On Earnings Yet Backed By Broader Checks
Simply Wall St. · Jul 10, 2026
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
Zacks · Jul 9, 2026
Are You Looking for a Top Momentum Pick? Why Bioventus (BVS) is a Great Choice
Zacks · Jul 8, 2026
Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know
Zacks · Jul 8, 2026
Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock?
Zacks · Jul 7, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held11.75%
Institutions Held78.33%
Institutions Float Held88.76%
Peer Comparison
About BVS
BVS is led by CEO Robert E. Claypoole, employs 930 people, headquartered in US, publicly traded since 2021.
BVS stock trades at $13.12 with a market capitalization of $888.85M. The stock is valued at a price-to-earnings (P/E) ratio of 20.85, price-to-book of 3.06, price-to-sales of 1.01. Over the past 52 weeks the stock has ranged between $5.81 and $13.12, and currently trades at its 52-week high.
On profitability, BVS generates a return on equity (ROE) of 16.46%, above the typical market average, return on capital employed of 25.76%, an operating margin of 10.64%, a net profit margin of 4.94%.